EDTUTC-4 New YorkLog in Sign up

SGMT
Sagimet Biosciences Inc. Series A Common Stock
stockNASDAQ

Market OpenOct 5, 2026 1:21:16 PM EDT

8.95USD-2.079%(-0.19)812,258

8.9400Bid8.9600Ask0.0200Spread

Pre-marketOct 5, 2026 9:29:59 AM EDT

9.07USD-0.711%(-0.06)

SGMT News

Day breaks

05:41 PM EDTSagimet closes down after acne drug denifanstat data, closing of stock offering ·

Seeking Alpha

04:31 PM EDTSagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants ·

GlobeNewswire Inc.

07:42 PM EDTSagimet Biosciences Inc. (SGMT) Discusses 52-Week Phase 3 Data and U.S. Phase 3 Plans for Denifanstat in Moderate to Severe Acne Transcript ·

Seeking Alpha

07:48 AM EDTSagimet Prices $115 Mln Stock Offering, Pre-market Shares Up ·

RTTNews

07:12 AM EDTAt a glance: stocks gapping up premarket ·

Seeking Alpha

06:31 AM EDTSagimet Biosciences stock rises after pricing $115M securities offering ·

Seeking Alpha

06:19 AM EDTSagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series A Common Stock and Pre-Funded Warrants ·

GlobeNewswire Inc.

06:00 AM EDTSagimet Announces Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026 ·

GlobeNewswire Inc.

07:00 AM EDTSagimet Biosciences to Host Virtual KOL Event, “Denifanstat Update: 52-Week Data from Phase 3 Open-Label Extension in China and Planned AURORA Phase 3 Clinical Trial in US” on September 30, 2026 ·

GlobeNewswire Inc.

03:17 AM EDTMarket Movers | Winners: SRZN, MNTK, CD | Losers: LRMR, ACAD, SGMT ·

Trefis

09:37 AM EDTUnited Therapeutics, Sagimet drop after Goldman Sachs Sell ratings ·

Seeking Alpha

07:00 AM EDTSagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026 ·

GlobeNewswire Inc.